CIA
BBIO icon

Choate Investment Advisors’s BridgeBio Pharma BBIO Stock Holding History

Choate Investment Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,270
Closed -$114K – 325
2022
Q1 		$114K Buy
+11,270
New +$116K 0.01% 305

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Choate Investment Advisors's BBIO Position: Q2 2022 in Review

Choate Investment Advisors sold out of BridgeBio Pharma (BBIO) in Q2 2022, closing a stake of 11,270 shares — an estimated $114K sold.

Choate Investment Advisors first reported a position in BBIO in Q1 2022 and held it in 1 quarter. The position peaked at $114K in Q1 2022. 164 funds tracked by Wall St. Rank hold BBIO as of Q2 2022.

  • Choate Investment Advisors reported no remaining BridgeBio Pharma position as of Q2 2022 after selling out during the quarter.
  • Choate Investment Advisors sold 11,270 BridgeBio Pharma shares in Q2 2022, an estimated $114K.
  • Choate Investment Advisors first reported a position in BridgeBio Pharma in Q1 2022 and held it in 1 quarter.
  • Choate Investment Advisors's BridgeBio Pharma position peaked at $114K in Q1 2022.
  • 164 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2022.

Based on Choate Investment Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.